Schedule 13G ownership disclosure
Lexeo Therapeutics Inc
Common Stock · CUSIP: 52886X107
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- JANUS HENDERSON GROUP PLC
Shares: 4,339,254 · Class: 13.1%
- Janus Henderson Biotech Innovation Master Fund Ltd
Shares: 2,503,168 · Class: 7.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001274173-25-000055
- Form type
- SCHEDULE 13G/A
- Filer
- JANUS HENDERSON GROUP PLC
- CIK
- CIK 1274173
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership